13 results
10-K
2024 FY
IXHL
Incannex Healthcare Limited
30 Sep 24
Annual report
7:30am
.
As controlled substances, the products may generate public controversy. Physicians, patients, payers or the medical community may be unwilling to accept … professionals.
Our drug candidates contain cannabinoid and psychedelic substances, the use of which may generate public controversy. Adverse publicity
S-1/A
IXHL
Incannex Healthcare Limited
17 Jul 24
IPO registration (amended)
8:47am
advantages over other treatment methods.
As controlled substances, the products may generate public controversy. Physicians, patients, payers
S-1
IXHL
Incannex Healthcare Limited
3 Jul 24
IPO registration
6:29am
of adverse side effects; and
other advantages over other treatment methods.
As controlled substances, the products may generate public controversy
20-F
2022 FY
IXHL
Incannex Healthcare Limited
28 Oct 22
Annual report (foreign)
6:31am
other treatment methods.
As controlled substances, the products may generate public controversy. Physicians, patients, payers or the medical
20FR12B/A
dje1 ldo3i
24 Feb 22
Initial registration of securities (foreign private issuers) (amended)
3:42pm
20FR12B/A
o912r42p
22 Feb 22
Initial registration of securities (foreign private issuers) (amended)
6:10am
20FR12B
70k7ssxw65 jpg
24 Jan 22
Initial registration of securities (foreign private issuers)
8:18pm
F-1/A
ptji ae853m
7 Dec 21
Registration statement (foreign) (amended)
5:21pm
F-1/A
wy7k v0sb7sjvonc
23 Nov 21
Registration statement (foreign) (amended)
3:28pm
F-1/A
hs61vjan
3 Nov 21
Registration statement (foreign) (amended)
6:06am
F-1/A
xr5izw2a c8e
28 Sep 21
Registration statement (foreign) (amended)
6:06am
F-1
dwcdo x0w
17 Aug 21
Registration statement (foreign)
4:39pm
- Prev
- 1
- Next